[ad_1]
The drugs Vamizim (alphaelosulfase) and Naglazyme (galsulfase) have just been included in the SUS (Sistema Único de Saúde) by the CONITEC (National Commission for the Integration of Technologies). Both drugs are used in the treatment of mucopolysaccharidosis (MPS) types IV A and VI.
The decision to include the drugs should benefit hundreds of patients who will have to go to court for free treatment. a feat for thousands of families who, after years of searching for a diagnosis, have led a long battle to get treatment for their children's disease, "says Dr. Carolina Fischinger, a member of the Brazilian Society of Medical genetics. "From now on, every patient diagnosed with such types of MPS will also have access to these SUS treatments in a structured way."
It is important to remember that the patient diagnosed with MPS is directly dependent of treatment to survive.
Diagnosed in young people
The young Júlia Rezende, 21 years old, was diagnosed with MPS type VI and during one had no access to This lack of treatment has compromised my cardiac and respiratory system. In addition, it forced me to perform several surgeries, "explains Júlia
" When I started taking the medicine, my image stabilized. MPS are rare genetic diseases of lysosomal deposits.
[196459002] MPS are rare genetic diseases of lysosomal deposits (MPS). which, due to the absence of certain enzymes, causes an accumulation of toxic substances in the cells of the body, involving a series of complications, such as a small size, characteristics of the disease, orthopedic problems and joint, cardiac and respiratory disorders, among others [19659002] The absence of enzyme replacement therapy may compromise the quality of life of the patient and worsen its prognosis
[ad_2]
Source link
